# A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma

> **NCT01413178** · PHASE3 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 205 (actual)

## Conditions studied

- Myeloma

## Interventions

- **DRUG:** Busulfan
- **DRUG:** Melphalan
- **OTHER:** Questionnaire
- **DRUG:** G-CSF
- **DRUG:** High Dose Melphalan
- **PROCEDURE:** Stem cell transplant

## Key facts

- **NCT ID:** NCT01413178
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09-30
- **Primary completion:** 2019-03-10
- **Final completion:** 2019-03-10
- **Target enrollment:** 205 (ACTUAL)
- **Last updated:** 2020-04-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01413178

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01413178, "A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01413178. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*